A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy

For estrogen receptor (ER)-negative breast cancer patients, paclitaxel (P), doxorubicin (A) and cyclophosphamide (C) neoadjuvant chemotherapy (NAC) is the standard therapeutic regimen. Pathologic complete response (pCR) and residual disease (RD) are common surrogate measures of chemosensitivity. Aft...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Mol Biosci
Autors principals: Chen, Yanhua, Cai, Hao, Chen, Wannan, Guan, Qingzhou, He, Jun, Guo, Zheng, Li, Jing
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Molecular Biosciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7109260/
https://ncbi.nlm.nih.gov/pubmed/32269999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fmolb.2020.00034
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars